Compare AUID & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AUID | XLO |
|---|---|---|
| Founded | 2009 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.6M | 41.8M |
| IPO Year | N/A | 2021 |
| Metric | AUID | XLO |
|---|---|---|
| Price | $1.24 | $0.72 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | ★ 3.6M | 648.7K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,834,458.00 | ★ $31,804,000.00 |
| Revenue This Year | N/A | $589.60 |
| Revenue Next Year | N/A | $38.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 141.81 | ★ 588.40 |
| 52 Week Low | $1.15 | $0.62 |
| 52 Week High | $9.58 | $1.70 |
| Indicator | AUID | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 34.69 | 43.26 |
| Support Level | $1.15 | $0.69 |
| Resistance Level | $1.38 | $0.75 |
| Average True Range (ATR) | 0.23 | 0.04 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 7.89 | 30.90 |
AuthID Inc is a company engaged in ensuring cyber-savvy enterprises Know Who's Behind the Device, for every customer or employee login and transaction. Through its easy-to-integrate, patented, biometric identity platform, authID quickly and accurately verifies a user's identity, eliminating any assumption of who is behind a device and preventing cybercriminals from taking over accounts. authID combines digital onboarding, biometric password less authentication and account recovery, with a fast, accurate, user-friendly experience-delivering identity verification.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.